The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Charlotte Ling receives a million-dollar grant from the Novo Nordisk Foundation

Charlotte Ling. Photo: Sara Liedholm.
Charlotte Ling. Photo: Sara Liedholm.

Charlotte Ling, Professor of Epigenetics at Lund University, is receiving DKK 10 million from the Novo Nordisk Foundation for a research project relating to epigenetics and type 2 diabetes. She is one of a total of 38 research group leaders who are receiving funding through the Novo Nordisk Foundation’s Research Leader Programme.

The project is called “Pancreatic islet dysfunction and epigenetic modifications in type 2 diabetes” and will run for five years.

Congratulations, Charlotte Ling! What is your research project about?

“The project is about studying epigenetic changes in the pancreas of diabetics and non-diabetics, who serve as control subjects, to discover epigenetic changes that cause type 2 diabetes. We also plan to investigate whether epigenetic changes may constitute new specific targets for the treatment of the disease.”

What benefits may the project yield?

“Our hope is that our efforts will lead to a new knowledge and views about how type 2 diabetes occurs and thus how the disease should be treated. If our unique project succeeds, it will have great significance for individuals as well as on a societal level.”

What does the grant mean for your work?

“The grant means that we can develop new methods that measure epigenetic changes in human cells. At the same time, I can retain my talented coworkers and colleagues in my research group, which is important for our continued success in this area.”

See press releases from the Novo Nordisk Foundation